Publications for Peter F Wright, MD https://geiselmed.dartmouth.edu/faculty/facultydb/view.php?uid=4098 Publications for Peter F Wright, MD en-us <![CDATA[Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.]]> https://www.ncbi.nlm.nih.gov/pubmed/42051288 bioRxiv. 2026 Feb 5; pii: 2026.02.04.703921. doi: 10.64898/2026.02.04.703921. Epub 2026 Feb 5.
PMID: 42051288]]> <![CDATA[Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.]]> https://www.ncbi.nlm.nih.gov/pubmed/42006303 iScience. 2026 Apr 17;29(4):115433. doi: 10.1016/j.isci.2026.115433. Epub 2026 Mar 20.
PMID: 42006303]]> <![CDATA[Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns.]]> https://www.ncbi.nlm.nih.gov/pubmed/40907970 Clin Infect Dis. 2026 Feb 25;82(2):e352-e360. doi: 10.1093/cid/ciaf484.
PMID: 40907970]]> <![CDATA[The Search for a Respiratory Syncytial Virus Vaccine.]]> https://www.ncbi.nlm.nih.gov/pubmed/40856553 NEJM Evid. 2025 Sep;4(9):EVIDe2500194. doi: 10.1056/EVIDe2500194. Epub 2025 Aug 26.
PMID: 40856553]]> <![CDATA[Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial.]]> https://www.ncbi.nlm.nih.gov/pubmed/40818478 Lancet Infect Dis. 2025 Dec;25(12):1363-1376. doi: 10.1016/S1473-3099(25)00285-3. Epub 2025 Aug 13.
PMID: 40818478]]> <![CDATA[Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials.]]> https://www.ncbi.nlm.nih.gov/pubmed/40318674 Lancet Microbe. 2025 Jun;6(6):101028. doi: 10.1016/j.lanmic.2024.101028. Epub 2025 Apr 30.
PMID: 40318674]]> <![CDATA[Binding and neutralising antibodies to respiratory syncytial virus and influenza A virus in serum and bronchoalveolar lavage fluid of healthy adults in the United States: A cross-sectional study.]]> https://www.ncbi.nlm.nih.gov/pubmed/40037127 Vaccine. 2025 Apr 19;53:126936. doi: 10.1016/j.vaccine.2025.126936. Epub 2025 Mar 3.
PMID: 40037127]]> <![CDATA[Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2.]]> https://www.ncbi.nlm.nih.gov/pubmed/38933606 Pathog Immun. 2024;9(2):1-24. doi: 10.20411/pai.v9i2.679. Epub 2024 Jun 18.
PMID: 38933606]]> <![CDATA[Nasal and Pharyngeal Mucosal Immunity to Poliovirus in Children Following Routine Immunization With Inactivated Polio Vaccine in the United States.]]> https://www.ncbi.nlm.nih.gov/pubmed/38809190 J Infect Dis. 2024 Nov 15;230(5):e1023-e1030. doi: 10.1093/infdis/jiae264.
PMID: 38809190]]> <![CDATA[SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations.]]> https://www.ncbi.nlm.nih.gov/pubmed/37620337 Nat Commun. 2023 Aug 24;14(1):5171. doi: 10.1038/s41467-023-40960-0. Epub 2023 Aug 24.
PMID: 37620337]]>